Speros
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Georgia, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1101 Chatham Pkwy Bldg C, Savannah, Geor...Phone Number
(912) 354-8900Website
www.speros.comRevenue
$9.3 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Speros
Located in the United States, Speros offers, surveillance, web design, phone systems, and IT services. The company maximizes technology to help business succeed in this fast-paced, technology driven world.Explore more
Speros Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Speros your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Speros recently announced quarterly report
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Speros has new funding data
Speros, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Speros had a recent Job posting/layoffs
Product Launch: Get notified when Speros launches new products
Congratulate Masked Content for being promoted to Masked Content at Speros
Check out if Speros is spiking on competitors!
Check if Speros has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Speros as Masked Content
Find more new buyers
Compare Similar Companies to Speros
Compare insights from companies similar to Speros, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Speros is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Speros is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Speros.
Speros Tech Stack
A closer look at the technologies used by Speros
Most Recent Scoops
Person-Based
Person-Based
Left Company
Executive Move
Jason Ryals, Chief Technology Officer, has left the organization.
Executive Moves, Personnel Moves, Left Company
Left Company
Executive Move
Speros News & Media
Spero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial
CAMBRIDGE, Mass., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that the United States Food and Drug Administration (FDA) informed Spero that a clinical hold has been placed on its Phase 2a clinical trial of SPR720, Spero’s investigationaSpero Therapeutics Announces First Patient Dosed with SPR720 in Phase 2a Clinical Trial in Patients with Nontuberculous Mycobacterial Pulmonary Disease
CAMBRIDGE, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections, today announced that it has initiated dosing in patients with nontuberculous mycobacterial pulmonary disease (NTM-PD) in its dose-ranging Phase 2a clinical trial of SPR720, Spero’s oral antimicrobial agSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on September 30, 2020 the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 37,000 shares of itSpero Therapeutics Announces FDA Acceptance of IND Application for SPR720
CAMBRIDGE, Mass., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections, today announced the acceptance by the U.S. Food and Drug Administration (FDA) of Spero’s Investigational New Drug application (IND) for SPR720, Spero’s oral antimicrobial agent in development for the tre
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Speros
Sign Up For FreeTo access detailed company insights
Located in the United States, Speros offers, surveillance, web design, phone systems, and IT services. The company maximizes technology to help business succeed in this fast-paced, technology driven world.... Read More
